Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy

Author(s): Maddalena de Virgilio, Franco Silvestris.

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 19 , 2011

Become EABM
Become Reviewer

Abstract:

The urokinase receptor (uPAR) exerts essential functions in the pathophysiology of cancers and therefore constitutes an important drug target. In order to generate efficient drugs against uPAR, a new approach includes chimeric proteins associating one molecular address to specifically target uPAR and one bacterial or plant toxin that will eventually kill the tumoral cell. Using this frame, several recombinant toxins have been designed namely DTAT, DTAT13, EGFATFKDEL 7 mut, and ATF-SAP. As molecular address, all of these fusion proteins use the amino-terminal fragment of urokinase that binds with high affinity to uPAR through its growth factor domain (GFD). The various toxin moieties were derived from either diphtheria toxin, Pseudomonas exotoxin A (PE38), or saporin. In this review, we describe the rational, design, production and therapeutic anti-cancer potential of these chimeric toxins.

Keywords: Cancer therapy, uPAR, ATF, saporin, diphtheria toxin, Pseudomonas exotoxin A, recombinant expression, BTLs, heterotopic toxicity, Ribosome Inactivating Proteins, immunotoxins, leukemias, antitumoral activity, endocytic receptors, potency

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 19
Year: 2011
Page: [1979 - 1983]
Pages: 5
DOI: 10.2174/138161211796718170
Price: $58

Article Metrics

PDF: 5